Composition and uses thereof
US-9821046-B2 · Nov 21, 2017 · US
Anti-malarial compositions
US10160802B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10160802-B2 |
| Application number | US-201615056458-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 29, 2016 |
| Priority date | Dec 5, 2013 |
| Publication date | Dec 25, 2018 |
| Grant date | Dec 25, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.
First claim
Opening claim text (preview).
The invention claimed is: 1. A cDNA molecule comprising a coding sequence for a variable region of a heavy chain of an antibody, wherein the variable region comprises: (i) a first heavy chain complementarity determining region (CDR H ) comprising the amino acid sequence SEQ ID NO:1; a second CDR H comprising the amino acid sequence SEQ ID NO:2; and a third CDR H comprising the amino acid sequence SEQ ID NO:3; or (ii) the complementarity determining regions of the heavy chain variable region of the antibody deposited under Accession No. MRA-1242. 2. The cDNA molecule of claim 1 , wherein the variable region comprises the first CDR H comprising the amino acid sequence SEQ ID NO:1; the second CDR H comprising the amino acid sequence SEQ ID NO:2; and the third CDR H comprising the amino acid sequence SEQ ID NO:3. 3. The cDNA molecule of claim 1 , wherein the variable region comprises the complementarity determining regions of the heavy chain of the antibody deposited under Accession No. MRA-1242. 4. A cDNA molecule, comprising a coding sequence for a variable region of a light chain of an antibody, wherein the variable region comprises: (i) a first CDR L comprising the amino acid sequence SEQ ID NO:4; a second CDR L comprising the amino acid sequence SEQ ID NO:5; and a third CDR L comprising the amino acid sequence SEQ ID NO:6; or (ii) the complementarity determining regions of the light chain variable region of the antibody deposited under Accession No. MRA-1242. 5. The cDNA molecule of claim 4 , wherein the light chain variable region comprises the first CDR L comprising the amino acid sequence SEQ ID NO:4; the second CDR L comprising the amino acid sequence SEQ ID NO:5; and the third CDR L comprising the amino acid sequence SEQ ID NO:6. 6. The cDNA molecule of claim 4 , wherein the light chain variable region comprises the complementarity determining regions of the light chain of the antibody deposited under Accession No. MRA-1242. 7. The cDNA molecule of claim 3 , further comprising a coding sequence for a light chain variable region comprising the complementarity determining regions of the antibody deposited under Accession No. MRA-1242.
Assignees
Inventors
Classifications
Antimalarials · CPC title
Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title
comprising antibodies · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10160802B2 cover?
- This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.
- Who is the assignee on this patent?
- Leidos Inc, Us Health, Us Health
- What technology area does this patent fall under?
- Primary CPC classification C07K16/205. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).